Kadmon Holdings, Inc.

KDMN

$3.42

+52.03% (1 year change)

Avg closing price

Price range

Market Cap

$685 Million

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$448 Thousand

Total revenue in the last quarter.

Net Income

$-27.2 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-0.93

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-4.28x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-26.9 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

115

The number of full time employees.

Revenue & Earnings

Balance Sheet

Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

News

Kadmon Holdings (KDMN) Investor Presentation - Slideshow (NYSE:KDMN)

Kadmon Holdings (KDMN) Investor Presentation - Slideshow (NYSE:KDMN)

The following slide deck was published by Kadmon Holdings, Inc. in conjunction with this event..

Seeking Alpha Seeking Alpha, about 1 month ago
Kadmon : and Meiji Announce Collaboration to Develop and Commercialize KD025 in Japan | MarketScreener

Kadmon : and Meiji Announce Collaboration to Develop and Commercialize KD025 in Japan | MarketScreener

Kadmon and Meiji Announce Collaboration to Develop and Commercialize KD025 in Japan NEW YORK and TOKYO December 26, 2019 - Kadmon Holdings, Inc. , a New York-based… | December 26, 2019

MarketScreener MarketScreener, 10 months ago
The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer

The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, In...

Benzinga Feeds Benzinga Feeds, 10 months ago